Navigation Links
Telik Announces Preclinical Presentations at AACR Annual Meeting
Date:4/7/2008

PALO ALTO, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced that four abstracts highlighting results from its Research and Development programs will be presented at the 99th annual meeting of the American Association for Cancer Research (AACR) in San Diego.
Details of the presentations are as follows:

-- Identification and Characterization of Novel Tyrosine Kinase Inhibitors

Targeting Vascular Endothelial Growth Factor Receptor 2; Sunday, April

13, 2008, 1:00 - 5:00pm; Experimental and Molecular Therapeutics 10;

Abstract # 1439

-- Mechanism of Induction of Apoptosis by TLK199 (Telintra(R)) in Human

Leukemia Cell Lines; Monday, April 14, 2008, 8:00am - 12noon;

Experimental and Molecular Therapeutics 10; Abstract # 2270

-- Identification of a Novel Class of Nonpeptidyl Small-Molecule

Inhibitors of the Human Proteasome; Monday, April 14, 2008,

1:00 - 5:00pm; Experimental and Molecular Therapeutics 28;

Abstract # 3271

-- Target-Related Affinity Profiling (TRAP(R)): Efficient Cancer Drug

Discovery at Telik; Tuesday, April 15, 2008; 1:00 - 5:00pm; Cancer

Chemistry 11; Abstract # 4754

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates.

TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome
2. DARA Announces Information in Compliance with NASDAQ Rules
3. Journey Lite of Thousand Oaks Announces Special Spring Price Discount In Response to Effects of Softening Economy on Patients Pocketbooks
4. VA Announces SGLI and VGLI Premium Reductions
5. London Luxury LLC Announces Exclusive Partnership with Cupron, Inc., to Develop Innovative Copper-Infused Bed and Bath Products
6. Boston Scientific Announces Appointment of Timothy Pratt as General Counsel
7. Accuri Cytometers Announces Commercial Launch of Revolutionary Accuri C6 Flow Cytometer(TM) System
8. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
9. QED International Associates Announces Changes to the HealthShares(TM) Cardio Devices Index (As Revised)
10. Smart Balance Announces Sales Organization Appointments
11. Global Action Board of Directors Announces Addition of Newest Member, Robert Hernreich
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Appleton, Wis. (PRWEB) , ... February 12, 2016 ... ... its second Lean Leadership Series at Zuckerberg San Francisco General Hospital on April ... to practice new behaviors and create new habits. The workshops cover a broad ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Fisher House Foundation ... Mayor John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns ... the VA Southern Nevada Healthcare System. This will be the first Fisher House ...
(Date:2/12/2016)... ... 12, 2016 , ... Vail knee specialist Robert LaPrade, MD, PhD ... . The list consists of physicians establishing, leading and partnering with ambulatory surgery centers ... An Ambulatory Surgery Center, also known as an ASC, is a modern health care ...
(Date:2/12/2016)... ... 12, 2016 , ... Donor Network West, the organ procurement organization that heals ... with San Ramon Regional Medical Center. Under the collaboration, the first of its kind, ... accommodate a more certain time frame for donor families for the recovery of organs. ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... surrounding communities by continuing it’s commitment to act as Agents of Change in ... works closely with area homeless families to fulfill immediate needs and help them ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... --> ... Global Clinical Trials Review, H2, 2015 provides an ... trials landscape along with top level data related ... & E7), Trial Status, Trial Phase, Sponsor Type ... involved and enlists all trials (Trial title, Phase, ...
(Date:2/11/2016)... 11, 2016 Stem cells are primitive cells ... self-renewal and the capacity to differentiate into mature cell ... as the first mouse embryonic stem cells were derived ... 1995 that the first culturing of embryonic stem cells ... not produced until 2006 As a result of these ...
(Date:2/11/2016)... -- Kindred Biosciences, Inc. (NASDAQ: KIN ), a biopharmaceutical ... pets, today announced the submission to FDA of the ... (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive topline results ... the control of pyrexia (fever) in horses were recently ... --> The Chemistry, Manufacturing, and Controls technical ...
Breaking Medicine Technology: